Compare ARK Genomic Revolution ETF (ARKG) vs Expedia Group Inc (EXPE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ARK Genomic Revolution ETF vs Expedia Group Inc — how do they compare? ARK Genomic Revolution ETF trades at $41.28, while Expedia Group Inc trades at $265.33 (market cap $32.51B). The key difference: Expedia Group Inc pays a 0.65% dividend while ARK Genomic Revolution ETF pays none, and ARK Genomic Revolution ETF is trading nearer its 52-week high, Expedia Group Inc nearer its low. Which is the better fit depends on your goals.
| ARKG | EXPE | |
|---|---|---|
Sector | Sector/Thematic | Consumer Cyclical |
52-Week High | $43.57 | $301.31 |
52-Week Low | $23.09 | $178.06 |
Market Cap | — | $32.51B |
Enterprise Value | — | $31.42B |
Dividend Yield | — | 0.65% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ARKG trades at $41.32, down 3.91% today, with a bullish technical signal driven by moving averages. Recent news highlights biotech ETF strength in June 2026, fueled by strong earnings, M&A activity, and AI-driven drug discovery optimism. Key support lies at $40, with resistance at $44.
The outlook remains positive given sector tailwinds, but risks include regulatory hurdles and market volatility. Investor sentiment is buoyed by industry growth catalysts, though selective investment approaches are noted by analysts.
Expedia Group (EXPE) trades at $270.83, up 1.14% with a bullish technical signal and strong fundamental performance. The stock shows consistent earnings beats, with Q1 2026 EPS of $1.96 exceeding expectations by 39%. Revenue growth has accelerated from $11.7B in 2022 to $14.7B in 2025, while net income margins improved to 9.81%. Recent developments include the CarTrawler acquisition and AI initiatives, positioning the company for continued travel sector leadership.
Outlook remains positive with analyst consensus target of $285.44 offering 5.4% upside. Key opportunities include travel demand recovery and operational efficiency gains, while risks involve macroeconomic sensitivity and competitive pressures. The stock presents a balanced risk-reward profile with strong institutional support and improving financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ARK Genomic Revolution ETF
ARKG is an actively managed ETF that invests in the genomic revolution. It focuses on companies leading in gene editing, CRISPR technology, therapeutics, and molecular diagnostics, including firms like CRISPR Therapeutics and Tempus AI.
Read more on ARKG →About Expedia Group Inc
Expedia is the world's largest online travel agency by bookings, offering services for lodging (75% of total 2021 sales), air tickets (3%), rental cars, cruises, in-destination, and other (15%), and advertising revenue (7%). Expedia operates a number of branded travel booking sites, including Expedia.com, Hotels.com, Travelocity, Orbitz, Wotif, AirAsia, and Vrbo. It has also expanded into travel media with the acquisition of Trivago. Transaction fees for online bookings account for the bulk of sales and profits.
Read more on EXPE →
